25 September 2020
VivaGel® BV secures TGA approval for prevention of BV
23 September 2020
2020 Annual General Meeting
23 September 2020
Appendix 2A
18 September 2020
Change in substantial holding
17 September 2020
Change in substantial holding
17 September 2020
Starpharma to present at OTCQX Life Sciences Investor Forum
14 September 2020
SPL7013 COVID-19 nasal spray virucidal against SARS-CoV-2
3 September 2020
Change in substantial holding
3 September 2020
Starpharma awarded $1M MRFF funding for COVID-19 spray
1 September 2020
SPL creates slow release soluble DEP® remdesivir nanoparticle
1 September 2020
Change in substantial holding
27 August 2020
Annual report and full year financial results
27 August 2020
Appendix 4G - Corporate Governance Statement
25 August 2020
SPL7013 nasal spray for COVID-19 – development update
17 August 2020
Starpharma signs new DEP® partnership with Chase Sun
30 July 2020
DEP® docetaxel and gemcitabine combination trial commences
30 July 2020
Quarterly Cashflow and Activities Report
27 July 2020
AZD0466 trial opens MD Anderson Cancer Center as a site
9 July 2020
New Australian site opening for DEP® trials
29 June 2020
DEP® irinotecan boosts immuno-oncology in colon cancer models

Investor Relations

For general questions about Starpharma Holdings Limited, please contact us at:

T: +61 3 8532 2700
E: investor.relations@starpharma.com


This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.